Business description
Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive monitoring technologies. In 1995, the company debuted Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, which has been shown in multiple studies to significantly reduce false alarms and accurately monitor for true alarms. Masimo SET® has also been shown to helps clinicians reduce severe retinopathy of prematurity in neonates, improve CCHD screening in newborns, and, when used for continuous monitoring in post-surgical wards, reduce rapid response activations and costs.
Management board & Supervisory board
| CEO |
| Joe E. Kiani |
| Management board |
| Micah Young, Bilal Muhsin, Tao Levy, Tom McClenahan |
| Supervisory board |
| Joe E. Kiani, Adam Mikkelson, Craig B. Reynolds, Dr. Julie A. Shimer, H. Michael Cohen |
Company data
| Name: |
Masimo Corp. |
| Address: |
52 Discovery,Irvine, California 92618, USA |
| Phone: |
+1-949-297-7000 |
| Fax: |
- |
| E-mail: |
-
|
| Internet: |
www.masimo.com |
| Industry: |
Healthcare |
| Sector: |
Healthcare Providers |
| Sub sector: |
Healthcare Providers |
| End of financial year: |
12-31 |
| Free Float: |
60.90% |
| IPO date: |
- |
Investor relations
| Name: |
Eli Kammerman |
| IR phone: |
+1-949-297-7077 |
| IR Fax: |
- |
| IR e-mail: |
ekammerman@masimo.com
|
